TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
--Versant Ventures-founded company integrating chemical biology and covalent ligand discovery at scale to drug previously intractable cancer targets-- --Collaboration with MD Anderson to enable translation of targets to clinical studies--WATERTOWN, Mass.
-Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials - - Cybin expects to report Phase 2 topline efficacy data for CY
MINNEAPOLIS--(BUSINESS WIRE)--SunOpta Inc. ("SunOpta" or the “Company”) (Nasdaq:STKL) (TSX:SOY), a U.S.-based global pioneer fueling the future of sustainable, plant-based and fruit-based foods and beverages, today announced that the Company will issu
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”), recently announced an update on the Sales and Investment Solicitation Process (the “SISP”) implemented as part of its ongoing proceedings under the Companies' Creditor
WINNIPEG, Manitoba--(BUSINESS WIRE)--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE) announced today that the Company’s second quarter 2023 financial results will be released after market close on Thursday, August 10, 2023. At th
WINNIPEG, Manitoba--(BUSINESS WIRE)--#bioMB--On June 6, the Manitoba government and Bioscience Association Manitoba (BAM) announced the first-ever Manitoba Life Sciences Strategy, marking a significant milestone for the province’s bioscience sector. Thi
OTTAWA, Ontario--(BUSINESS WIRE)--BioTalent Canada is pleased to announce that it has reopened its popular Science Horizons program that provides employers in the environmental and clean-technology sectors with wage subsidies to hire post-secondary STEM g
First and only medication authorized in Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome. Approval supported by more than six years of LIVMARLI data demonstrating improvements in pruritus and serum bile acids. Data f
PTAB rejects request by Berkeley Lights to reconsider its decision denying Berkeley's argument that AbCellera’s U.S. patent is invalidVANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) announced that the United States Patent
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.